QuANTUM-Wild Phase 3 Trial of VANFLYTA® Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML [Yahoo! Finance]
DAIICHI SANKYO S/ADR (DSNKY)
NASDAQ:AMEX Investor Relations:
daiichisankyo.com/media_investors/investor_relations/index.html
Company Research
Source: Yahoo! Finance
chemotherapy and as maintenance monotherapy in adult patients with newly diagnosed FLT3-ITD negative acute myeloid leukemia (AML). The trial aims to confirm the potential role of VANFLYTA in this broader population of patients with AML who are in need of new treatment options to potentially reduce the risk of relapse and improve overall survival. The trial is expected to enroll approximately 700 patients across Asia, Australia, Europe, North America, and South America. TOKYO & BASKING RIDGE, N.J., December 10, 2024 BUSINESS WIRE )--The first patient has been dosed in the QuANTUM-Wild phase 3 trial evaluating Daiichi Sankyo's (TSE: 4568) VANFLYTA ® (quizartinib) in combination with standard intensive induction and consolidation chemotherapy followed by single-agent maintenance in adults with newly diagnosed FLT3 -ITD negative acute myeloid leukemia (AML). AML is an aggressive blood cancer with a five-year overall survival rate of approximately 32%. Targeted therapy with FLT3 inhibi
Show less
Read more
Impact Snapshot
Event Time:
DSNKY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DSNKY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DSNKY alerts
High impacting DAIICHI SANKYO S/ADR news events
Weekly update
A roundup of the hottest topics
DSNKY
News
- Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily WithdrawnBusiness Wire
- Maker Of Chemicals For Sharper X-ray Images Is Newest Indian Billionaire [Forbes]Forbes
- QuANTUM-Wild Phase 3 Trial of VANFLYTA® Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AMLBusiness Wire
- Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung CancerBusiness Wire
- Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer in TROPION-Lung05 and TROPION-Lung01 Pooled AnalysisBusiness Wire